Author: kodiac

  • Lanreotide

    Synthetic cyclic octapeptide somatostatin analog with preferential somatostatin receptor subtype 2 and 5 agonism

    A cyclic octapeptide somatostatin analog developed by Beaufour-Ipsen as the second clinically available long-acting somatostatin receptor ligand, distinguished by a unique self-assembling supersaturated depot formulation, antiproliferative activity in gastroenteropancreatic neuroendocrine tumors demonstrated in the landmark CLARINET trial, and a three-indication regulatory portfolio spanning acromegaly, neuroendocrine tumor growth control, and carcinoid syndrome.

    Abstract

    Lanreotide (D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; CAS 108736-35-2 free base; molecular formula C54H69N11O10S2; molecular weight 1096.33) is a synthetic cyclic octapeptide analog of native somatostatin-14, developed by Beaufour-Ipsen (now Ipsen) and introduced clinically in the early 1990s as the second somatostatin analog to reach the market after octreotide. The compound exhibits high-affinity agonism at somatostatin receptor subtypes 2 and 5 (SSTR2, Ki approximately 0.54 to 0.75 nM; SSTR5, Ki approximately 5.2 nM) with moderate affinity at SSTR3 and low affinity at SSTR1 and SSTR4, a selectivity profile that mediates suppression of growth hormone, insulin-like growth factor 1, and multiple gastrointestinal and pancreatic hormones through inhibition of adenylyl cyclase and reduction of intracellular cyclic adenosine monophosphate [1, 2]. The compound is formulated as lanreotide acetate in the Autogel (marketed as Somatuline Depot in the United States), a supersaturated aqueous gel in which lanreotide molecules self-assemble into hollow nanotubes of highly uniform diameter stabilized by beta-sheet hydrogen bonding, hydrophobic packing, and aromatic pi-pi stacking, producing a deep subcutaneous depot that releases active peptide over 28 days with a terminal elimination half-life of 23 to 30 days and absolute bioavailability of approximately 60 to 70 percent [3, 4]. The Autogel formulation, first approved in Europe in 2001 and in the United States in 2007, was the first marketed sustained-release pharmaceutical product produced by peptide self-assembly rather than by polymer microsphere encapsulation. Three indications are registered in the United States: long-term treatment of acromegaly in patients who have had an inadequate response to or cannot be treated with surgery and radiotherapy (FDA approved August 2007); treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival (FDA approved December 2014, on the basis of the CLARINET trial); and treatment of carcinoid syndrome in adults to reduce the frequency of rescue somatostatin analog therapy (FDA approved February 2018, on the basis of the ELECT trial) [5, 6, 7]. In acromegaly, lanreotide Autogel at 60 to 120 mg every 28 days normalizes growth hormone to below 2.5 micrograms per liter in approximately 58 percent and age-adjusted insulin-like growth factor 1 in approximately 48 percent of treatment-naive patients, with tumor volume reduction in approximately 60 percent of evaluated patients on long-term treatment [8, 9]. In the CLARINET trial, lanreotide 120 mg every 28 days versus placebo produced a hazard ratio for progression or death of 0.47 (95 percent confidence interval 0.30 to 0.73; P less than 0.001) in 204 patients with nonfunctioning, somatostatin-receptor-positive, grade 1 or 2 enteropancreatic neuroendocrine tumors, with estimated 24-month progression-free survival of 65.1 percent versus 33.0 percent [6]. In the ELECT trial, lanreotide 120 mg every 28 days significantly reduced the need for rescue short-acting octreotide for symptomatic carcinoid syndrome control and reduced patient-reported days with moderate or severe diarrhea and flushing [7]. The principal adverse events at registered doses are gastrointestinal (diarrhea 26 to 65 percent, abdominal pain 7 to 34 percent, nausea 5 to 11 percent), cholelithiasis and gallbladder sludge (14 to 20 percent), injection site reactions (5 to 22 percent), dysglycemia (hyperglycemia 5 to 14 percent, hypoglycemia 2 to 7 percent), and sinus bradycardia (3 to 8 percent) [10]. This monograph reviews the chemistry, synthesis, and self-assembly of lanreotide; the somatostatin receptor pharmacology in molecular detail; the comprehensive human pharmacokinetic record; the preclinical antiproliferative pharmacology; the clinical evidence base across acromegaly, neuroendocrine tumor, and carcinoid syndrome indications; reconstitution and handling; sourcing and quality verification; stack-interaction considerations; adverse-event signal; and a comparative assessment of five somatostatin receptor ligands against lanreotide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1391Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Macimorelin

    Synthetic peptidomimetic growth hormone secretagogue receptor type 1a (GHS-R1a) agonist

    An orally active peptidomimetic ghrelin receptor agonist developed at the University of Montpellier and advanced by Aeterna Zentaris as the first and only approved oral diagnostic test for adult growth hormone deficiency, distinguished from other growth hormone secretagogues by its validated diagnostic application and favorable safety profile relative to the insulin tolerance test.

    Abstract

    Macimorelin (JMV-1843, EP-1572, AEZS-130), a synthetic peptidomimetic agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor), is the first and only orally administered diagnostic agent approved by the United States Food and Drug Administration (December 2017) and the European Medicines Agency (January 2019) for the evaluation of adult growth hormone deficiency (AGHD). The compound was invented and first synthesized at the University of Montpellier and the Centre National de la Recherche Scientifique (CNRS) in France by Fehrentz, Martinez, Guerlavais, and colleagues as part of a structure-activity program seeking orally bioavailable growth hormone secretagogues derived from the hexarelin scaffold, and was subsequently licensed to Aeterna Zentaris for clinical development and marketed under the trade names Macrilen (United States, Novo Nordisk) and Ghryvelin (European Union, Consilient Health and subsequently Pharmanovia) [1, 2]. Structurally, macimorelin is a modified tripeptide containing two indole (tryptophan-derived) moieties linked through a central peptidomimetic backbone with a terminal formamide group and an N-terminal alpha-aminoisobutyric acid cap, conferring oral bioavailability and resistance to proteolytic degradation that distinguish it from the earlier peptide-based growth hormone secretagogues such as GHRP-6 and hexarelin.

    The compound binds the GHS-R1a receptor on pituitary somatotroph cells with an IC50 of 22.9 nanomolar in human pituitary tissue and activates the Gq/11-phospholipase C signaling cascade, stimulating endogenous growth hormone release into the systemic circulation in a manner pharmacologically analogous to the endogenous ligand ghrelin [2, 3]. Following oral administration at the diagnostic dose of 0.5 mg/kg body weight, macimorelin produces a robust and reproducible rise in serum growth hormone concentration that peaks between 30 and 90 minutes post-dose, permitting diagnostic discrimination between growth hormone-sufficient and growth hormone-deficient adults through serial blood sampling over a 90-minute test window. The Phase 3 confirmatory trial (Garcia et al., 2018) in 157 adults demonstrated 87 percent sensitivity and 96 percent specificity at a growth hormone cutoff of 2.8 ng/mL, with 97 percent reproducibility on repeat testing, establishing macimorelin as a clinically validated alternative to the insulin tolerance test with the practical advantages of oral administration, absence of hypoglycemia risk, and a shorter, simpler test protocol [4, 5].

    Pharmacokinetics are characterized by rapid oral absorption (median time to peak plasma concentration approximately 0.75 hours), hepatic metabolism predominantly through cytochrome P450 3A4 (CYP3A4) to a partially active O-demethylated metabolite, a terminal elimination half-life of approximately 4.1 hours, approximately 70 percent plasma protein binding, and predominantly fecal excretion [6, 7]. Food substantially reduces both the rate and extent of absorption (Cmax reduction of approximately 55 percent, AUC reduction of approximately 44 to 49 percent with a high-fat meal), mandating overnight fasting before the diagnostic test. The principal drug interaction concern is with strong CYP3A4 inducers (which may reduce macimorelin exposure and produce false-positive diagnostic results) and strong CYP3A4 inhibitors (which may elevate exposure). The compound produces a mean increase in the corrected QT interval of approximately 11 milliseconds at the diagnostic dose, requiring avoidance of concomitant QT-prolonging medications during the test [8].

    Adverse events in clinical trials were mild and transient, with dysgeusia (bitter or metallic taste), dizziness, headache, nausea, fatigue, hunger, and diarrhea reported at low frequencies. No serious adverse events attributable to macimorelin were reported in the pivotal trials across more than 1000 administered subjects [5, 8]. The compound is administered as a single diagnostic dose rather than as a chronic therapeutic regimen, and the safety profile reflects this acute exposure context. Beyond the diagnostic indication, macimorelin has been investigated in cancer cachexia (pilot trial demonstrating safety and numerical weight improvement) and in pharmacoresistant epilepsy (preclinical seizure suppression through GHS-R1a-mediated neuroprotection), though the compound is not approved for any therapeutic application [9, 10].

    This monograph reviews the chemistry, synthesis, and structural pharmacology of macimorelin; the GHS-R1a receptor mechanism in molecular detail; the comprehensive human pharmacokinetic record; the preclinical and clinical evidence base across diagnostic and investigational applications; reconstitution and handling considerations; stack interactions and drug-drug interaction considerations; the adverse-event and safety signal; and a comparative assessment of five growth hormone secretagogue or diagnostic candidates (insulin tolerance test, glucagon stimulation test, anamorelin, ibutamoren, and GHRH-arginine test) against macimorelin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1419Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Ovagen

    Synthetic hepatoprotective tripeptide bioregulator of the Khavinson ultrashort peptide class

    A synthetic tripeptide (Glu-Asp-Leu) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a tissue-specific epigenetic bioregulator targeting hepatic and gastrointestinal gene expression, distinguished from conventional hepatoprotective agents by a proposed mechanism of direct nuclear peptide-DNA interaction and chromatin remodeling rather than receptor-mediated signal transduction.

    Abstract

    Ovagen is a synthetic tripeptide composed of L-glutamic acid, L-aspartic acid, and L-leucine (Glu-Asp-Leu; single-letter code EDL) and belongs to the Khavinson class of ultrashort peptide bioregulators developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson. The compound is classified as a liver and gastrointestinal tract bioregulator within the Cytogen (synthetic short-chain peptide) product line and is proposed to exert its biological activity through direct interaction with nuclear DNA and chromatin rather than through conventional membrane receptor signaling. The molecular weight of Ovagen is 375.37 daltons (molecular formula C15H25N3O8), a size that places it within the ultrashort peptide category (2 to 7 amino acid residues) characterized by resistance to gastrointestinal peptidase degradation, oral bioavailability without enteric coating in some formulations, and the capacity to cross cellular membranes and localize to the nucleoplasm without receptor-mediated endocytosis. The principal proposed mechanism of action involves sequence-specific binding of the EDL tripeptide to double-stranded DNA in the promoter regions of hepatocyte genes governing cell proliferation, antioxidant defense, apoptosis, and inflammatory signaling. In aged rat liver tissue, Ovagen administration has been reported to produce an approximately 18-fold increase in Ki-67 expression (a marker of cellular proliferation) and an approximately 6-fold decrease in p53 expression (a marker of apoptotic signaling and cellular senescence), suggesting a shift from senescent to proliferative hepatocyte phenotype [1, 2]. In preclinical models of chemically induced hepatotoxicity (carbon tetrachloride and paracetamol), Ovagen administration over 14 to 28 days reduced serum liver enzyme elevation, decreased hepatocyte necrosis and inflammatory cell infiltration on histological examination, and normalized hepatic antioxidant status [3, 4]. A secondary research application involves gastrointestinal mucosal support, with preclinical data suggesting that Ovagen strengthens epithelial barrier function, increases tight junction protein expression, and reduces intestinal permeability in aging models [5]. The compound has not been approved by any national regulatory authority for therapeutic use. No published, peer-reviewed human clinical trials of Ovagen exist as of the date of this monograph. The evidence base is entirely preclinical (cell culture and rodent models) and is derived predominantly from the Khavinson laboratory and collaborating Russian institutions. The peptide bioregulator framework within which Ovagen was developed has produced a substantial body of Russian-language and English-language literature, including a 2021 systematic review of peptide regulation of gene expression published in the journal Molecules [6], but the framework has not been independently validated by Western regulatory-standard clinical trials. Investigators considering Ovagen for research applications should weight the evidence accordingly, noting the predominantly single-laboratory provenance of the preclinical data, the absence of human pharmacokinetic characterization to Western regulatory standards, and the mechanistic novelty of the proposed direct peptide-DNA interaction pathway. This monograph reviews the chemistry, proposed mechanism of action, preclinical pharmacology, available pharmacokinetic considerations, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a comparative assessment of five hepatoprotective or liver-bioregulatory candidates against Ovagen on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1406Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pegvisomant

    PEGylated recombinant human growth hormone receptor antagonist

    A protein-engineered, PEGylated analog of human growth hormone carrying nine amino acid substitutions that confer high-affinity binding at growth hormone receptor site 1 and functional antagonism at site 2, developed as the first and only growth hormone receptor antagonist approved for the treatment of acromegaly refractory to surgery and radiation.

    Abstract

    Pegvisomant (B2036-PEG; trade name Somavert; CAS 218620-50-9) is a PEGylated recombinant human growth hormone (hGH) analogue engineered to function as a selective competitive antagonist of the growth hormone receptor (GHR), approved by the United States Food and Drug Administration in 2003 for the treatment of acromegaly in patients who have had an inadequate response to surgery, radiation therapy, or other medical therapies, or for whom these therapies are not appropriate. The compound consists of a 191-amino-acid polypeptide backbone (designated B2036) carrying nine amino acid substitutions relative to wild-type hGH: eight substitutions in the site 1 binding interface (His18Asp, His21Asn, Arg167Asn, Lys168Ala, Asp171Ser, Lys172Arg, Glu174Ser, Ile179Thr) that increase binding affinity for the first GHR molecule, and one substitution in the site 2 binding interface (Gly120Lys) that introduces a bulky lysine side chain preventing the conformational change required for functional receptor dimerization and activation of the JAK2-STAT5 signaling cascade [1, 2]. The B2036 protein is covalently conjugated with four to six polyethylene glycol (PEG) polymers of approximately 5 kDa each at lysine residues and the N-terminus, yielding a final molecular mass of approximately 42 to 52 kDa depending on PEGylation stoichiometry. PEGylation extends the plasma elimination half-life from approximately 15 minutes (unpegylated B2036) to 60 to 138 hours, reduces immunogenicity, and permits once-daily subcutaneous dosing [3, 4]. Pegvisomant was discovered in 1987 by John Kopchick and Wen Chen at the Edison Biotechnology Institute at Ohio University through transgenic mouse studies demonstrating that substitution of glycine 120 in the third alpha-helix of growth hormone with bulky amino acids abolished growth-promoting activity and created a functional antagonist of endogenous growth hormone action [1]. Sensus Drug Development Corporation licensed the technology and advanced the compound through clinical development with PEGylation applied to extend the pharmacokinetic profile. Pharmacia Corporation acquired Sensus in 2001 and was subsequently acquired by Pfizer. The FDA approved pegvisomant (Somavert) on March 26, 2003; the European Medicines Agency granted marketing authorization in November 2002 [5]. The mechanism of action is fundamentally distinct from the other medical therapies for acromegaly. Somatostatin receptor ligands (octreotide, lanreotide, pasireotide) and dopamine agonists (cabergoline) act at the pituitary level to suppress growth hormone secretion. Pegvisomant acts at the peripheral target organ level by competitively blocking GHR activation, thereby reducing hepatic production of insulin-like growth factor I (IGF-I), the principal mediator of the somatic and metabolic consequences of growth hormone excess. This peripheral mechanism renders pegvisomant effective regardless of pituitary tumor somatostatin receptor expression, GH secretory dynamics, or tumor histological subtype [2, 6]. In the pivotal Phase 3 randomized, double-blind, placebo-controlled trial reported by Trainer et al. (2000) in the New England Journal of Medicine, pegvisomant at 10, 15, and 20 mg daily subcutaneously for 12 weeks normalized serum IGF-I concentrations in 54, 81, and 89 percent of patients with acromegaly, respectively, compared to 10 percent on placebo [6]. Long-term surveillance data from the ACROSTUDY international observational registry, encompassing 2,221 patients followed for a median of 7.4 years, confirmed a favorable safety profile with IGF-I normalization rates reaching 75.4 percent at 10 years of treatment, pituitary tumor size increase in 7.1 percent by local reading, liver function abnormalities in 3.2 percent, and treatment-related adverse events leading to drug withdrawal in only 1.3 percent [7, 8]. Pharmacokinetics are characterized by slow subcutaneous absorption (time to peak concentration 33 to 77 hours), limited volume of distribution (approximately 7 liters), low renal clearance (less than 1 percent excreted unchanged in urine), and a long elimination half-life of 60 to 138 hours supporting once-daily dosing [3]. Bioavailability after subcutaneous injection is approximately 57 percent relative to intravenous administration. The compound does not cross the blood-brain barrier [9]. Approximately 17 percent of treated patients develop low-titer, non-neutralizing anti-growth hormone antibodies without apparent impact on efficacy [3]. The compound improves glucose metabolism and insulin sensitivity in acromegaly patients, an advantage over somatostatin analogues that may suppress insulin secretion and worsen glucose homeostasis [10, 11]. This monograph reviews the protein engineering, PEGylation chemistry, and structural pharmacology of pegvisomant; the molecular mechanism of growth hormone receptor antagonism; the comprehensive human pharmacokinetic record; preclinical pharmacology in transgenic and xenograft models; the clinical evidence base across the pivotal registration trial, long-term observational studies, and combination therapy investigations; sourcing and quality verification; reconstitution and handling; stack interactions with somatostatin receptor ligands, dopamine agonists, insulin, and other endocrine agents; the adverse-event and safety signal; and a structured comparative assessment of five alternative acromegaly pharmacotherapies (octreotide, lanreotide, pasireotide, cabergoline, and paltusotine) against pegvisomant on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1424Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pemvidutide

    Balanced dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist peptide with glycolipid half-life extension

    A 29-amino-acid unimolecular peptide engineered for equipotent GLP-1 and glucagon receptor co-agonism, conjugated to a proprietary glycolipid moiety for weekly subcutaneous dosing, under clinical development for metabolic dysfunction-associated steatohepatitis, obesity, and alcohol use disorder.

    Abstract

    Pemvidutide (ALT-801; CAS 2538014-94-5; UNII A35F525WBG; molecular formula C182H275N39O54; molecular weight 3873.42 g/mol) is a synthetic 29-amino-acid peptide that functions as a balanced (1:1) dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), developed by Altimmune, Inc. (Gaithersburg, Maryland) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The compound incorporates sequence elements derived from both GLP-1 and glucagon and is conjugated to an 18-carbon diacid alkyl chain through a proprietary glycosidic linkage (designated EuPort), which provides near-quantitative but transient binding to serum albumin and extends the plasma half-life to a duration consistent with once-weekly subcutaneous administration without dose titration [1, 2]. The dual receptor mechanism differentiates pemvidutide from selective GLP-1 receptor agonists such as semaglutide and liraglutide: GLP-1R activation suppresses appetite through hypothalamic and brainstem satiety circuits, delays gastric emptying, and improves glycemic control, while GCGR activation directly stimulates hepatic fatty acid beta-oxidation, suppresses de novo lipogenesis, and increases energy expenditure through thermogenic pathways, producing a composite antisteatotic and weight-reducing pharmacology that is mechanistically suited to liver-predominant metabolic disease [3, 4, 5]. In the translational AMLN diet-induced obese mouse model of NASH, pemvidutide at 10 nmol/kg subcutaneous produced approximately 25 percent body weight reduction, significant reductions in liver triglycerides, galectin-3, collagen type 1 alpha 1, and NAFLD Activity Score, with efficacy exceeding that of semaglutide and elafibranor at equimolar doses on composite histological endpoints [6]. Clinical development has advanced through Phase 1 studies (NCT04561245, 100 subjects), Phase 1b/2a studies in MASLD (NCT05006885, 95 subjects; NCT05292911, 64 subjects), the Phase 2 MOMENTUM obesity trial (391 subjects, 48 weeks), and the Phase 2b IMPACT trial in biopsy-confirmed MASH (NCT05989711, 212 subjects) [1, 7, 8, 9, 10]. In the Phase 1b/2a MASLD study (Harrison et al. 2025), 12 weeks of pemvidutide at 1.8 mg weekly produced a 68.5 percent relative reduction in liver fat content by MRI-proton density fat fraction versus 4.4 percent for placebo (p < 0.001), with 55.6 percent of treated subjects achieving liver fat normalization to 5 percent or below [8]. Extension to 24 weeks produced 75.2 percent liver fat reduction at 1.8 mg and 6.2 percent body weight reduction versus placebo [7]. In the MOMENTUM trial, pemvidutide at 2.4 mg weekly for 48 weeks produced mean weight loss of 15.6 percent versus 2.2 percent on placebo, with body composition analysis demonstrating 78.1 percent of weight loss attributable to fat mass and 21.9 percent to lean mass [9, 10]. In the Phase 2b IMPACT trial (Noureddin et al. 2025) in 212 patients with biopsy-confirmed MASH and fibrosis stages F2 or F3, pemvidutide met the primary endpoint of MASH resolution without fibrosis worsening: 59.1 percent at 1.2 mg and 52.1 percent at 1.8 mg versus 19.1 percent for placebo (p < 0.0001 for both comparisons) [11]. Topline 48-week data demonstrated continued antifibrotic activity with statistically significant improvements in Enhanced Liver Fibrosis score and liver stiffness measurement versus placebo [12]. The United States Food and Drug Administration has granted Breakthrough Therapy Designation for pemvidutide in MASH (January 2026) and Fast Track designations for both MASH and AUD [13, 14]. Phase 3 registrational programs for MASH and the VELOCITY Phase 3 program for obesity are in planning as of May 2026. Safety across completed trials has been favorable; adverse events are predominantly gastrointestinal (nausea, diarrhea, decreased appetite), mild to moderate in severity, and concentrated in the first 16 weeks of treatment. No imbalances in cardiac events, arrhythmias, or clinically meaningful heart rate increases have been observed. This monograph reviews the compound identification, structural pharmacology, mechanism of action, pharmacokinetics, preclinical and clinical evidence base, sourcing and quality verification, reconstitution and handling, stack interactions, adverse events, and a comparative assessment of five alternative agents (survodutide, semaglutide, tirzepatide, cotadutide, resmetirom) against pemvidutide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1410Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Octreotide

    Synthetic cyclic octapeptide somatostatin analog with preferential binding to somatostatin receptor subtypes 2 and 5

    A disulfide-bridged octapeptide analog of hypothalamic somatostatin-14 developed at Sandoz as SMS 201-995, distinguished from the native hormone by a 30-fold increase in inhibition of growth hormone release relative to insulin suppression and an elimination half-life extended from under 3 minutes to approximately 100 minutes after subcutaneous administration.

    Abstract

    Octreotide (SMS 201-995) is a synthetic cyclic octapeptide analog of somatostatin-14 that reproduces the pharmacologically essential tetrapeptide core (Phe-Trp-Lys-Thr) of the native hormone within a conformationally constrained disulfide-bridged ring, yielding a compound with high-affinity binding at somatostatin receptor subtype 2 (SSTR2; Ki approximately 0.4 to 0.6 nanomolar), moderate affinity at SSTR5 (Ki approximately 7 nanomolar) and SSTR3 (Ki approximately 35 nanomolar), and negligible affinity at SSTR1 and SSTR4 [1, 2]. The compound was synthesized at the Sandoz Forschungsinstitut in Basel by Bauer, Briner, Doepfner, and colleagues in 1982, selected from a series of conformationally stabilized somatostatin fragments on the basis of a 45-fold increase in potency for growth hormone inhibition relative to somatostatin-14 in an in vitro rat pituitary bioassay and a 30-fold selectivity for growth hormone suppression over insulin suppression, a therapeutic index absent from the native tetradecapeptide [1]. The critical structural innovation was the introduction of a D-Trp at position 4 and D-phenylalanol at the C-terminus within a cystine-bridged octapeptide ring that resisted enzymatic degradation and extended the plasma elimination half-life from the approximately 1 to 3 minutes of native somatostatin to approximately 90 to 120 minutes after subcutaneous injection in humans [3, 4]. Octreotide received United States Food and Drug Administration approval in 1988 for the symptomatic management of acromegaly and for the control of symptoms associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). The long-acting release (LAR) intramuscular depot microsphere formulation (Sandostatin LAR, Novartis) was approved in 1998, enabling once-monthly administration at 10, 20, or 30 milligram doses. An oral octreotide capsule formulation (Mycapssa, Chiasma/Amryt) employing a transient permeability enhancer technology received FDA approval in 2020 for long-term maintenance therapy in acromegaly patients previously responding to injectable somatostatin receptor ligands [5]. The antiproliferative activity of octreotide LAR in metastatic midgut neuroendocrine tumors was established in the PROMID trial (Rinke et al. 2009), a placebo-controlled randomized study demonstrating a median time to tumor progression of 14.3 months versus 6.0 months on placebo (hazard ratio 0.34, p equal to 0.000072) [6]. Pharmacokinetics after subcutaneous administration are characterized by rapid absorption (peak plasma concentration at 25 to 30 minutes), high bioavailability (approximately 100 percent), plasma protein binding of approximately 65 percent predominantly to lipoprotein, hepatobiliary metabolism, and renal elimination of approximately 32 percent of the dose as unchanged drug [3, 4]. The principal adverse effects are gastrointestinal (diarrhea, nausea, abdominal discomfort in 30 to 50 percent of patients, typically self-limiting), cholelithiasis (gallstone or biliary sludge formation in 15 to 30 percent on chronic therapy, attributable to inhibition of cholecystokinin-mediated gallbladder contraction and bile flow), and alterations in glucose homeostasis (suppression of insulin and glucagon secretion producing hyper- or hypoglycemia depending on the metabolic context) [7, 8]. This monograph documents the chemistry, synthesis, and structural pharmacology of octreotide; the somatostatin receptor subtype binding profile and downstream signaling; the comprehensive human pharmacokinetic record across subcutaneous, intramuscular depot, and oral formulations; the clinical evidence base across acromegaly, neuroendocrine tumors, carcinoid syndrome, VIPomas, variceal bleeding, and investigational indications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety record; and a structured comparative assessment of five somatostatin-pathway agents (lanreotide, pasireotide, pegvisomant, paltusotine, lutetium-177 DOTATATE) against octreotide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1390Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Mecasermin

    Recombinant human insulin-like growth factor 1 (rhIGF-1), a 70-amino-acid single-chain polypeptide with three intramolecular disulfide bonds

    A recombinant analog of endogenous insulin-like growth factor 1 developed at Genentech and commercialized by Tercica (later Ipsen) for the treatment of severe primary IGF-1 deficiency, distinguished from growth hormone replacement by its direct activation of the type 1 IGF-1 receptor and its investigational applications in neuroprotection, neurodevelopmental disorders, and metabolic disease.

    Abstract

    Mecasermin is recombinant human insulin-like growth factor 1 (rhIGF-1), a 70-amino-acid, 7649-dalton non-glycosylated polypeptide produced in Escherichia coli by recombinant DNA technology. The amino acid sequence of mecasermin is identical to that of endogenous human IGF-1, a peptide hormone synthesized principally in the liver under the transcriptional control of growth hormone and serving as the primary mediator of postnatal somatic growth, skeletal maturation, and metabolic homeostasis. Mecasermin is the active pharmaceutical ingredient in Increlex (Ipsen), the only therapy approved by the United States Food and Drug Administration (August 2005, priority review) and by the European Medicines Agency (2007) for the long-term treatment of growth failure in pediatric patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD), a condition most classically represented by Laron syndrome (growth hormone receptor deficiency) and by growth hormone gene deletion with neutralizing antibodies to exogenous growth hormone.

    The mechanism of action is direct agonism of the type 1 IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase structurally homologous to the insulin receptor. Ligand binding activates autophosphorylation of the intracellular kinase domain and recruitment of insulin receptor substrate (IRS) adapter proteins, leading to bifurcated downstream signaling through the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway (metabolic, anti-apoptotic, and translational outcomes) and the Ras/Raf/mitogen-activated protein kinase (MAPK/ERK) pathway (mitogenic, proliferative, and differentiative outcomes). In the growth plate, IGF-1R activation stimulates chondrocyte proliferation and hypertrophy in the proliferative and hypertrophic zones of the epiphyseal cartilage, driving longitudinal bone growth through endochondral ossification. The metabolic actions include stimulation of glucose uptake, amino acid incorporation into protein, fatty acid uptake, and suppression of hepatic glucose output, producing a composite anabolic and mildly hypoglycemic pharmacology.

    Pharmacokinetics following subcutaneous injection are characterized by near-complete bioavailability, a time to peak plasma concentration of approximately 2 hours, and a terminal elimination half-life that is critically dependent on circulating levels of IGF-binding protein 3 (IGFBP-3) and the acid-labile subunit (ALS). In patients with severe primary IGF-1 deficiency, who characteristically have low IGFBP-3 and ALS concentrations, the terminal half-life is approximately 5.8 hours; in healthy individuals with normal binding protein levels, the half-life extends to approximately 19 hours owing to sequestration in the 150-kilodalton ternary complex of IGF-1, IGFBP-3, and ALS. The volume of distribution is approximately 0.257 liters per kilogram. Clearance is inversely proportional to IGFBP-3 concentration and is estimated at 0.04 liters per hour per kilogram at an IGFBP-3 level of 3 micrograms per milliliter. Metabolism is predominantly lysosomal, principally in the liver and kidneys, with degradation to amino acids; less than 0.1 percent of administered drug is excreted unchanged in urine.

    The pivotal clinical evidence base consists of five open-label, single-arm studies in 71 pediatric patients with SPIGFD treated for a mean duration of 3.9 years (274 subject-years of exposure). First-year height velocity increased from a baseline of 2.6 centimeters per year to 8.0 centimeters per year (p less than 0.0001), with sustained growth acceleration over 8 or more years of continuous treatment. The principal adverse event is hypoglycemia, reported in 42 percent of subjects; severe hypoglycemia requiring assistance occurred in 5 subjects, and hypoglycemic seizures or loss of consciousness occurred in 4 subjects. Hypoglycemia is mitigated by administration within 20 minutes of a meal or snack. Other notable adverse events include tonsillar and adenoidal hypertrophy (15 percent), injection site lipohypertrophy, and intracranial hypertension with papilledema (3 subjects). Long-term safety monitoring has not identified an increased incidence of malignancy at approved doses. Investigational applications of mecasermin extend to Rett syndrome (Phase 1, with improvement in apnea and neurobehavioral parameters), amyotrophic lateral sclerosis (negative in controlled trials), and various neuroprotective contexts supported by the neurotrophic properties of IGF-1.

    This monograph reviews the chemistry and recombinant production of mecasermin; the IGF-1R signaling pharmacology in molecular detail; the comprehensive pharmacokinetic record including binding protein dependence; the clinical evidence base across growth failure, neuroprotection, and metabolic indications; sourcing and quality verification for research-grade material; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative growth-promoting or IGF-1-axis compounds against mecasermin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1422Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pasireotide

    Multi-receptor somatostatin analog with preferential somatostatin receptor subtype 5 agonism

    A second-generation cyclohexapeptide somatostatin analog developed at Novartis as a multi-receptor-targeted antisecretory agent, distinguished from first-generation analogs by broad somatostatin receptor subtype binding with preferential affinity for sst5 and approved for Cushing’s disease and acromegaly.

    Abstract

    Pasireotide (SOM230) is a synthetic cyclohexapeptide somatostatin analog and the first medical therapy approved by the United States Food and Drug Administration for the treatment of Cushing’s disease, subsequently extended to acromegaly in a long-acting release formulation. Structurally distinct from the linear and octapeptide first-generation somatostatin analogs octreotide and lanreotide, pasireotide incorporates key pharmacophoric elements of native somatostatin-14 into a metabolically stable cyclohexapeptide scaffold containing unnatural amino acids, conferring broad binding across four of the five human somatostatin receptor subtypes (sst1, sst2, sst3, and sst5) with a binding affinity profile that is 30-fold higher at sst1, 5-fold higher at sst3, and 40-fold higher at sst5 compared to octreotide, while retaining comparable affinity at sst2 [1, 2]. The preferential sst5 agonism is the principal pharmacological differentiator: corticotroph adenoma cells in Cushing’s disease express sst5 at substantially higher density than sst2, and the sst5-mediated suppression of adrenocorticotropic hormone (ACTH) secretion is the molecular basis for the efficacy of pasireotide in this indication where first-generation sst2-preferring analogs are ineffective [3, 4]. In a 12-month Phase 3 study of 162 patients with Cushing’s disease (Colao et al. 2012, New England Journal of Medicine), subcutaneous pasireotide at 600 or 900 micrograms twice daily produced a median reduction in urinary free cortisol of approximately 50 percent by month 2 with normalization of urinary free cortisol in 15 to 26 percent of patients at month 6 [5]. In acromegaly, the Phase 3 PAOLA study (Gadelha et al. 2014, Lancet Diabetes and Endocrinology) demonstrated superior biochemical control with pasireotide long-acting release (LAR) at 40 and 60 mg monthly versus continued first-generation somatostatin analog therapy in patients inadequately controlled on octreotide or lanreotide, with 15 to 20 percent of pasireotide-treated patients achieving both growth hormone below 2.5 micrograms per liter and normalized insulin-like growth factor 1 versus zero percent in the active control group [6]. Pharmacokinetics after subcutaneous administration are characterized by rapid absorption (time to peak approximately 0.25 to 1 hour), a terminal elimination half-life of approximately 12 hours, hepatic clearance predominantly through biliary excretion, and dose-proportional exposure across the clinical dose range [7, 8]. The principal safety liability is hyperglycemia, observed in 73 percent of Cushing’s disease patients in the Phase 3 study, mechanistically attributable to sst5-mediated suppression of insulin secretion and reduction of incretin hormones (glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide) from enteroendocrine cells, a predictable on-target effect that is manageable with antidiabetic agents and reversible upon discontinuation [9, 10]. Other adverse events include gastrointestinal symptoms (diarrhea, nausea, abdominal pain), cholelithiasis, hepatic transaminase elevations, QT interval prolongation on electrocardiogram, and bradycardia, a profile broadly consistent with the somatostatin analog class [11]. This monograph reviews the chemistry, synthesis, and structural pharmacology of pasireotide; the multi-receptor mechanism in molecular detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology across pituitary, neuroendocrine, and oncologic models; the clinical evidence base across Cushing’s disease, acromegaly, and neuroendocrine tumor indications; reconstitution, sourcing, and handling considerations; stack-interaction implications; adverse-event signal; and a comparative assessment of five somatostatin receptor agonist candidates against pasireotide on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1392Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Mecasermin rinfabate

    Recombinant human insulin-like growth factor-1 and insulin-like growth factor binding protein-3 equimolar binary complex (rhIGF-1/rhIGFBP-3)

    A recombinant equimolar binary protein complex of human IGF-1 and its principal binding protein IGFBP-3, developed by Insmed as iPLEX for subcutaneous replacement therapy in severe primary IGF-1 deficiency and subsequently investigated in amyotrophic lateral sclerosis and complications of extreme prematurity.

    Abstract

    Mecasermin rinfabate (International Nonproprietary Name; brand name iPLEX) is a pharmaceutical-grade equimolar binary complex of recombinant human insulin-like growth factor-1 (rhIGF-1, 70 amino acids, 7,649 Da) and recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3, 264 amino acids, approximately 28,700 Da unglycosylated), produced in Escherichia coli expression systems and formulated for subcutaneous injection at a combined molecular weight of approximately 36,381 daltons. The complex was designed to replicate the physiological binary association of IGF-1 with its most abundant circulating binding protein, thereby extending the plasma half-life of administered IGF-1 from approximately 10 to 20 minutes (free rhIGF-1) to approximately 13 to 21 hours (complexed form), reducing hypoglycemic risk relative to unbound IGF-1, and enabling once-daily subcutaneous dosing in contrast to the twice-daily regimen required for mecasermin (rhIGF-1 alone, marketed as Increlex). Upon subcutaneous administration, the binary complex associates with endogenous acid-labile subunit (ALS) to form the approximately 150 kDa ternary complex that represents the principal physiological reservoir of circulating IGF-1, thereby normalizing the IGF-1 axis in patients with deficient endogenous production.

    The compound received United States Food and Drug Administration approval on December 12, 2005 (NDA 021884) for the treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (Primary IGFD) or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. The approved dose range was 0.5 to 2.0 mg/kg administered once daily by subcutaneous injection, titrated to achieve physiological IGF-1 levels measured 8 to 18 hours post-dose. Clinical development was conducted in two cohort studies enrolling 36 children and adolescents with primary IGFD, predominantly growth hormone receptor deficiency (Laron syndrome), demonstrating statistically significant dose-dependent increases in height velocity from a pre-treatment baseline of approximately 3 to 4 cm/year to 6 to 9 cm/year during the first year of treatment.

    The commercial trajectory of mecasermin rinfabate was truncated by patent litigation. In March 2007, Insmed Incorporated settled a patent infringement action brought by Tercica (the manufacturer of mecasermin/Increlex) by agreeing to withdraw iPLEX from the United States market for all short stature indications and to abandon its European regulatory application for these uses. The settlement extinguished the primary commercial indication. Insmed subsequently investigated mecasermin rinfabate in amyotrophic lateral sclerosis (ALS) under both clinical trial and compassionate-use frameworks; a Phase II randomized controlled trial in 330 ALS patients failed to demonstrate benefit on muscle strength, need for tracheostomy, or survival at the end of a two-year treatment period. More recently, the rhIGF-1/rhIGFBP-3 complex (under the development name of the successor product) has been investigated by Shire (now Takeda) and collaborators in extremely preterm infants for prevention of retinopathy of prematurity and other complications of prematurity, with a Phase 2 randomized controlled trial (NCT01096784) demonstrating a 53 percent decrease in severe bronchopulmonary dysplasia but no reduction in retinopathy of prematurity severity.

    The pharmacology of mecasermin rinfabate is that of its constituent IGF-1 moiety acting through the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase that activates the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase (MAPK/ERK) signaling cascades to promote linear growth, cellular proliferation, differentiation, and survival. The IGFBP-3 moiety serves as a pharmacokinetic modulator, extending half-life and buffering against acute hypoglycemia, while also exerting IGF-independent effects including proapoptotic activity through nuclear receptor interactions and antiproliferative signaling in certain cellular contexts. The principal adverse events at approved doses are hypoglycemia (31 percent), headache (22 percent), arthralgia, injection site reactions, and lymphadenopathy. Safety data beyond 21 months of continuous treatment have not been established. This monograph reviews the molecular composition, development history, mechanism of action, pharmacokinetics, clinical evidence base across all studied indications, handling considerations, adverse-event profile, and a comparative assessment of five IGF-1 axis therapeutics against mecasermin rinfabate on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1423Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Maritide

    Bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism

    A first-in-class bispecific antibody-peptide conjugate developed at Amgen that pairs a fully human monoclonal glucose-dependent insulinotropic polypeptide receptor antagonist antibody with two covalently linked glucagon-like peptide 1 analogue agonist peptides, yielding a long-acting once-monthly injectable for chronic weight management distinguished from existing incretin therapeutics by simultaneous GIP receptor blockade and an approximately 21-day elimination half-life.

    Abstract

    Maridebart cafraglutide (MariTide; development code AMG 133) is a first-in-class bispecific peptide-antibody conjugate engineered at Amgen by covalent attachment of two glucagon-like peptide 1 (GLP-1) receptor agonist peptide analogues to a fully human immunoglobulin G2 (IgG2) monoclonal antibody that functions as a potent antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). The molecule was designed to exploit the additive weight-loss pharmacology of simultaneous GLP-1 receptor (GLP-1R) activation and GIP receptor blockade, a mechanistic combination that in preclinical diet-induced obese mouse and cynomolgus monkey models produced greater body-weight reduction than either moiety alone. In cell-based functional assays the compound demonstrates GLP-1R agonist activity with EC50 values of 24.4 picomolar (human), 5.7 picomolar (cynomolgus monkey), 2.4 picomolar (rat), and 123 picomolar (mouse), and GIPR antagonist activity with IC50 values of 46.4 nanomolar (human), 26.5 nanomolar (cynomolgus monkey), and 822.3 nanomolar (rat) [1, 2]. The antibody scaffold confers a terminal elimination half-life of approximately 21 days in humans after subcutaneous administration, approximately three-fold longer than the longest-acting approved once-weekly GLP-1 receptor agonists, and supports once-monthly or less frequent dosing [1]. In a Phase 1 randomized, double-blind, placebo-controlled single- and multiple-ascending-dose study (NCT04478708) in 163 adults with obesity, maridebart cafraglutide produced dose-dependent weight loss of up to 14.5 percent at 12 weeks with weight loss maintained for up to 150 days after the final dose, accompanied by an acceptable safety and tolerability profile in which gastrointestinal adverse events (nausea, vomiting) were predominantly mild and transient [1]. A Phase 2 dose-ranging study (NCT05669599) in 592 adults with obesity with or without type 2 diabetes randomized to subcutaneous maridebart cafraglutide at 140, 280, or 420 mg every four weeks or 420 mg every eight weeks versus placebo for 52 weeks demonstrated mean weight loss of 12.3 to 20 percent in participants without type 2 diabetes and 8.4 to 17 percent in participants with type 2 diabetes, with HbA1c reductions of up to 2.2 percentage points, without evidence of a weight-loss plateau at 52 weeks [3, 4]. The Phase 2 study further reported no clinically significant changes in bone mineral density and body-composition data indicating that the majority of weight lost was fat mass rather than lean tissue. Gastrointestinal adverse events were the most common treatment-emergent events and were mitigated by dose escalation from a lower starting dose; discontinuation rates due to gastrointestinal events were approximately 8 percent with dose escalation compared with 12 to 27 percent without [3, 4]. Amgen initiated the Phase 3 MARITIME program in 2025, comprising chronic weight management trials (MARITIME-1 in obesity without type 2 diabetes, MARITIME-2 in obesity with type 2 diabetes) with planned 72-week treatment duration and primary readouts expected in early 2027, as well as planned Phase 3 cardiovascular outcomes, heart failure, and obstructive sleep apnea studies [5, 6]. The compound is not approved by any regulatory authority as of the monograph date. This monograph documents the molecular design and structural biology of the peptide-antibody conjugate; the dual-receptor pharmacology at GLP-1R and GIPR in molecular and cellular detail; the preclinical pharmacology in rodent and primate models; the comprehensive human pharmacokinetic record; the clinical evidence base across Phase 1 and Phase 2 obesity and type 2 diabetes endpoints; sourcing and handling considerations; stack-interaction implications; adverse-event profile; and a comparative assessment of five incretin-class obesity therapeutics against maridebart cafraglutide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1412Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.